Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
buy vibrator.
Popular Articles

Veterinary Practices In UK Need Good Access To Occupational Health
Staff working in UK veterinary practices lack access to good occupational health advice warns a new study published in the scientific journal, Occupational Medicine. The research, the first published benchmark of occupational health risk management by vet practices in the UK, showed that despite veterinary surgeons and nurses being exposed to many occupational hazards less than a third of practices had trained staff in health and safety and only 14% sought advice from occupational health professionals.
pharmacy online
Australian Medical Association: Rural Health A Bright Spot In Budget
Measures contained in the budget will help attract and retain more doctors to rural and remote areas, the AMA said today.
News of the day
Norway Chooses The Four-Type HPV Vaccine Gardasil(R) For The National Vaccination Programme
The four-type (6,11,16,18) human papillomavirus (HPV) vaccine, Gardasil®, has been chosen by the Norwegian authorities for the national vaccination programme after the assessment of a variety of criteria, including efficacy in the prevention of cervical cancer, safety and evidence of long-lasting protection. All available data was considered, including new data presented during the 25th International Papillomavirus Conference (IPC) in May in Malmē¶, Sweden.
Endocrinology

LATITUDE Pharmaceuticals Initiates Two More Collaboration Studies For Its PG Depot

LATITUDE Pharmaceuticals, Inc. (LPI), a San Diego-based drug formulation developer, announced today that it has initiated two new collaboration programs for its Phospholipid Gel (PG) Depot drug delivery platform. The programs are designed to provide prolonged and peak-free pharmacokinetic profiles for 3 and 7 days following a subcutaneous injection for an antibiotic and a protein drug, respectively. The new studies bring the total to seven feasibility/license agreements that are applying the PG Depot to deliver small molecules, peptides, and proteins for pain, metabolic disease, anti-bacterial, and cardiovascular applications. Andrew Chen, PhD, LPI"s president, noted, "Our newest feasibility studies represent a growing validation of our PG Depot technology. Like our ongoing collaborations, the new programs aim to transform a cumbersome routine of multiple injections each day into a convenient once-daily or once-weekly format. Both pharma and biotech companies definitely see high value in simplifying parenteral drug administration and extending or resurrecting IP protection through novel delivery technology. The protein-friendly nature of the PG Depot will create many opportunities to convert biologics from daily to weekly injections." About PG Depot LPI"s proprietary PG Depot technology is a versatile parenteral drug delivery platform for small molecules and biological therapeutics that delivers 1-7 days of low burst, peak-free sustained drug release following a subcutaneous or intramuscular injection. The PG Depot is provided as a single-phase, ready-to-use, self-administration-capable gel that is injectable through fine (27G or smaller) needles. The gel is compatible with hydrophilic and hydrophobic small molecule drugs as well as peptides and proteins and can be manufactured using conventional processes. Because it is composed of FDA-approved injectable and biodegradable ingredients, the PG Depot has key advantages over other depot systems, which use new polymers or animal-derived materials and face ever-increasing safety hurdles at the FDA and other regulatory agencies. LATITUDE Pharmaceuticals, Inc.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009